Specific intravenous carbohydrate therapy: a new approach to the inhibition of antibody-mediated rejection following ABO-incompatible allografting and discordant xenografting.
Cooper
D K
DK
Oklahoma Transplantation Institute, Baptist Medical Center, Oklahoma City 73112.
Good
A H
AH
Ye
Y
Y
Koren
E
E
Oriol
R
R
Ippolito
R M
RM
Malcolm
A J
AJ
Neethling
F A
FA
Romano
E
E
Zuhdi
N
N
D000017:ABO Blood-Group System / Q000276:immunology*; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology; D001787:Blood Group Incompatibility; D002236:Carbohydrate Conformation; D002240:Carbohydrate Sequence; D006084:Graft Rejection / Q000276:immunology* / Q000517:prevention & control; D006085:Graft Survival / Q000276:immunology; D016027:Heart Transplantation / Q000276:immunology* / Q000502:physiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D016030:Kidney Transplantation / Q000276:immunology; D008969:Molecular Sequence Data; D009844:Oligosaccharides / Q000008:administration & dosage / Q000276:immunology / Q000494:pharmacology*; D010215:Papio; D013552:Swine; D014183:Transplantation, Heterologous / Q000276:immunology*; D014184:Transplantation, Homologous / Q000276:immunology
D000017:ABO Blood-Group System; D000888:Antibodies, Anti-Idiotypic; D007166:Immunosuppressive Agents; D009844:Oligosaccharides